{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:44:02Z","timestamp":1790844242897,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,4,30]],"date-time":"2009-04-30T00:00:00Z","timestamp":1241049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The prognosis of chronic lymphocytic leukaemia (CLL) patients is largely determined by the karyotype of the malignant clone. We have investigated the gene expression profile associated with trisomy 12 (+12).<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Initially, unselected peripheral blood mononuclear cells of four patients with +12 were compared with 16 CLL controls using microarray analysis. Results were validated by quantitative real\u2010time PCR with RNA from 61 patients (29 with +12, 32 CLL controls).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Seven genes showing the strongest correlation with +12 in microarray analysis were selected for real\u2010time PCR: <jats:italic>HIP1R<\/jats:italic>, <jats:italic>MYF6<\/jats:italic>, <jats:italic>SLC2A6<\/jats:italic>, <jats:italic>CD9<\/jats:italic> (overexpressed); <jats:italic>CD200<\/jats:italic>, <jats:italic>P2RY14<\/jats:italic>, <jats:italic>RASGRP3<\/jats:italic> (underexpressed). Four genes were significantly associated with +12: <jats:italic>HIP1R<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001), <jats:italic>MYF6<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7007), <jats:italic>P2RY14<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7014), <jats:italic>CD200<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7028). Receiver Operating Characteristic curve analysis revealed that <jats:italic>HIP1R<\/jats:italic> expression was a highly sensitive and specific marker for +12 in CLL patients. <jats:italic>MYF6<\/jats:italic> was exclusively expressed in normal or malignant B cells in peripheral blood but was poorly predictive for +12. As expected, a number of overexpressed genes are located on chromosome 12 (<jats:italic>HIP1R<\/jats:italic>, <jats:italic>MYF6<\/jats:italic>). Interestingly, both significantly underexpressed genes (<jats:italic>P2RY14<\/jats:italic>, <jats:italic>CD200<\/jats:italic>) reside on the long arm of chromosome 3 pointing to trans\u2010repression in this region.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Analysis of the molecular signature of trisomy 12 in CLL resulted in: (i) identification of a surrogate marker for PCR (<jats:italic>HIP1R<\/jats:italic>); (ii) observation of a gene dosage effect; and (iii) detection of specific underexpression of genes located on chromosome 3. These results should help to improve diagnosis and treatment decisions for patients with CLL and trisomy 12.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02146.x","type":"journal-article","created":{"date-parts":[[2009,4,30]],"date-time":"2009-04-30T13:43:07Z","timestamp":1241098987000},"page":"568-575","source":"Crossref","is-referenced-by-count":27,"title":["Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12"],"prefix":"10.1111","volume":"39","author":[{"given":"E.","family":"Porpaczy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bilban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vanura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Schwarzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Streubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fonatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1677"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200007000-00005"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331606"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.134"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2516"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3639"},{"key":"e_1_2_7_12_2","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1023"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.133"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190127505"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2146"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402537"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1892"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20390"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404220"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.568"},{"key":"e_1_2_7_26_2","volume-title":"SEER Cancer Statistics Review 1973\u20131991: Tables and Graphs, NIH Publication No. 94\u20102789","author":"Gloecklet Ries L","year":"1994"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<891::AID-SIM780>3.0.CO;2-B"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12319"},{"key":"e_1_2_7_29_2","first-page":"769","article-title":"Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect","volume":"17","author":"Dickinson JD","year":"2006","journal-title":"Int J Mol Med"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404935"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.021"},{"key":"e_1_2_7_32_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1598.1598","article-title":"CD200: a new target for immunotherapy in hematologic malignancies","volume":"112","author":"Brunetti C","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.1.5"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.2.699"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00923-08"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.05.037"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02146.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:15:16Z","timestamp":1697231716000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02146.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,5]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02146.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02146.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,5]]}}}